文献速递牙周病

从蛋白质组到治疗:牙周炎药物发现的多数据库探索性初步研究

From the Proteome to Therapeutics: A Multi-Database Approach to Drug Discovery in Periodontitis-An Exploratory Pilot Study.
PubMed 文献 · J Clin Periodontol · 2026-05-04

该探索性初步研究利用唾液蛋白质组学结合药物靶点数据库筛选,在两个独立样本(队列N=187、病例对照N=72)中识别与牙周炎相关的蛋白质,并评估已批准药物能否重定位用于牙周炎治疗。严格标准下仅1个蛋白质在两项研究中均与牙周炎相关,宽松标准下为26个;数据库筛选识别出3/11种已批准药物,其中8种具有牙周治疗重定位潜力。

要点

  • 唾液蛋白质组学联合药物靶点数据库可筛选牙周炎重定位药物。
  • 严格标准下仅1个蛋白质在两项研究中与牙周炎相关。
  • 宽松标准下26个蛋白质相关,其中9个为已报道药物靶点。

核心结论

  • 该探索性初步研究为牙周炎治疗提供了潜在治疗靶点和潜在药物的见解。
  • 该工作流程可能有助于识别可重定位用于牙周治疗的已批准药物。

研究设计与样本

  • 采用唾液LC-MS/MS蛋白质组分析,在两个独立设置中进行:队列研究(子研究I,N=187)和病例对照研究(子研究II,N=72)。
  • 统计分析采用严格和宽松两种标准,并检索四个数据库评估蛋白质是否为已批准药物的已知靶点。

主要发现

  • 严格标准下1个蛋白质在两项研究中均与牙周炎相关;宽松标准下为26个。
  • 严格标准下1个相关蛋白质为已报道药物靶点;宽松标准下9个为已报道药物靶点。
  • 严格标准下1个已报道药物靶点为牙周炎潜在药物靶点;宽松标准下7个为潜在药物靶点。
  • 数据库靶点筛选识别出3/11种已批准药物,其中8种具有牙周治疗重定位潜力。
  • 部分药物(如HDAC抑制剂、sivelestat、compstatin衍生物、auranofin、artenimol和bortezomib)已在牙周宿主调节的临床前模型中显示疗效。

关键数值与推荐

  • 严格标准:队列研究中q值<0.05且病例对照研究中p值<0.05及绝对倍数变化>1.5。
  • 宽松标准:队列研究中q值<0.1且病例对照研究中p值<0.05及绝对倍数变化>1.3。

临床怎么用

  • 该工作流程可为识别牙周炎重定位药物提供参考。
  • 筛选出的已批准药物可能作为牙周治疗重定位的候选。

局限性

  • 本研究为探索性初步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug-target database screening. METHODS: Proteomic analyses of saliva using LC-MS/MS were conducted in two independent settings: a cohort (sub-study I, N = 187) and case-control (sub-study II, N = 72). Statistical analyses were performed using both stringent and lenient criteria. Under the stringent (lenient) criteria, proteins were considered potential targets if they showed a q-value < 0.05 (< 0.1) in the cohort study and a p-value < 0.05 together with an absolute fold change > 1.5 (1.3) in the case-control study. Four databases were searched to assess whether these proteins are known targets of approved drugs. RESULTS: In the stringent (lenient) analysis one (26) proteins were associated with periodontitis in both studies, of which one (nine) were reported drug targets and one (seven) of those were potential drug targets in periodontitis. Target screening in databases identified 3/11 approved drugs, with eight of them having potential for repurposing for periodontal treatment. Several of these drugs (e.g., HDAC inhibitors, sivelestat, compstatin derivatives, auranofin, artenimol and bortezomib) have already shown efficacy in preclinical models of periodontal host modulation. CONCLUSION: This exploratory pilot study provided insights into potential therapeutic targets and potential drugs for periodontitis treatment. This workflow may help to identify approved drugs that could be repurposed for periodontal treatment.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Bozo T, Murr A, Holtfreter B, et al. From the Proteome to Therapeutics: A Multi-Database Approach to Drug Discovery in Periodontitis-An Exploratory Pilot Study. J Clin Periodontol. 2026. PMID: 42083475. doi:10.1111/jcpe.70129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。